Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flarin (ibuprofen)
- Development stage
- Approved
- Lead developer
- Infirst Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flarin is a unique lipid-based formulation of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), developed by Infirst Healthcare. This formulation encapsulates ibuprofen in a lipid matrix, which is designed to enhance the drug's solubility and absorption while potentially improving gastrointestinal tolerability compared to standard ibuprofen formulations. In 2020, researchers at King's College London and Guy's and St Thomas' NHS Foundation Trust initiated the LIBERATE (Lipid Ibuprofen in COVID-19 Acute Respiratory Failure) trial to evaluate Flarin's potential in hospitalized patients with COVID-19. The study aimed to determine if early intervention with this lipid-ibuprofen formulation could reduce the severity of lung injury and prevent the progression to acute hypoxemic respiratory failure by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby mitigating the systemic inflammatory response and prostaglandin-mediated lung damage associated with severe viral infection.
- Brand names
- Flarin
- Other names
- lipid ibuprofenliquid-filled ibuprofen capsules
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Flarin (ibuprofen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flarin (ibuprofen).